GW Pharmaceuticals (GWPH)
Whenever a discussion of marijuana stocks materializes, GW Pharmaceuticals (GWPH) isn’t one of the names brought up.
But maybe it should be.
The value of GWPH stock has doubled this year alone on the heels of one and only product — Sativax. Sativex is a cannabinoid-based medicine that treats spasticity in multiple sclerosis patients, approved in several countries (though not yet in the United States).
The drug could be approved to do much more than that, however. Sativex also has shown great promise as a therapy for cancer pain, and GW Pharmaceuticals is developing other cannabinoids to treat epilepsy, type 2 diabetes and more.
The advantage GWPH might have over other marijuana stocks is that it’s an established, clearly legitimate company, with $47.6 million in sales for the past four quarters to show for it.